{"id":563,"date":"2015-01-27T16:00:45","date_gmt":"2015-01-27T16:00:45","guid":{"rendered":"http:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/?p=563"},"modified":"2017-08-21T12:01:38","modified_gmt":"2017-08-21T12:01:38","slug":"primary-care-corner-with-geoffrey-modest-md-hiv-2-infection","status":"publish","type":"post","link":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/2015\/01\/27\/primary-care-corner-with-geoffrey-modest-md-hiv-2-infection\/","title":{"rendered":"Primary Care Corner with Geoffrey Modest MD: HIV-2 infection"},"content":{"rendered":"<p><strong>By: Dr. Geoffrey Modest\u00a0<\/strong><\/p>\n<p>I have a patient with HIV-2 infection on darunavir\/ritonavir plus truvada (tenof, FTC), who had a sharp increase in CD4 from 180 to 350 after starting meds, stable at 300-350 range for the past couple of years, then (when I was finally able to check an HIV-2 viral load, which was a send-out to Washington University) was found to have a viral load of 3000. After speaking with folks in San Francisco (the HIV consultation line, also called the warm-line), they suggested getting in contact with Dr. Geoffrey Gottlieb at Washington\u00a0University. He has an experimental assay for checking HIV-2 resistance, and when I emailed him, he responded immediately that he would get the most recent viral load sample from the lab there, sent last week, and do resistance testing. So, thought I would pass that on. He wrote the up-to-date chapter on HIV2 treatment. Also see a\u00a0really good review of HIV-2 therapy (<strong>doi:10.1016\/j.antiviral.2013.12.001<\/strong>).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>HIV-2 infection [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary understrap-read-more-link\" href=\"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/2015\/01\/27\/primary-care-corner-with-geoffrey-modest-md-hiv-2-infection\/\">Read More&#8230;<\/a><\/p>\n","protected":false},"author":148,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[14283],"tags":[],"class_list":["post-563","post","type-post","status-publish","format-standard","hentry","category-archive"],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/posts\/563","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/users\/148"}],"replies":[{"embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/comments?post=563"}],"version-history":[{"count":0,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/posts\/563\/revisions"}],"wp:attachment":[{"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/media?parent=563"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/categories?post=563"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stg-blogs.bmj.com\/bmjebmspotlight\/wp-json\/wp\/v2\/tags?post=563"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}